MyoKardia has announced the promising results of Phase III clinical trials of its lead drug mavacamten for symptomatic, obstructive hypertrophic cardiomyopathy (HCM).
Following the announcement, shares of the California-based company skyrocketed. The Phase III clinical trial - EXPLORER-HCM – demonstrated the potential of the drug in effectively treating HCM and, and it met all the primary and secondary end-points. The company now plans to file for an early 2021 New Drug Application.
Mavacamten is a first-in-class small molecule drug that reversibly binds to myosin targeting the excess contractility and impaired relaxation underlying hypertrophic cardiomyop...
